company background image
CSL

CSLASX:CSL Stock Report

Last Price

AU$264.52

Market Cap

AU$126.6b

7D

-4.2%

1Y

-3.7%

Updated

22 Jan, 2022

Data

Company Financials +
CSL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends0/6

CSL Stock Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

CSL Competitors

Johnson & Johnson

NYSE:JNJ

US$434.0b

Pfizer

NYSE:PFE

US$296.3b

Eli Lilly

NYSE:LLY

US$220.4b

Novo Nordisk

CPSE:NOVO B

kr.1.4t

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share PriceAU$264.52
52 Week HighAU$319.78
52 Week LowAU$242.00
Beta0.059
1 Month Change-9.36%
3 Month Change-10.59%
1 Year Change-3.67%
3 Year Change32.82%
5 Year Change134.34%
Change since IPO32,965.33%

Recent News & Updates

Jan 19
Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Does the January share price for CSL Limited ( ASX:CSL ) reflect what it's really worth? Today, we will estimate the...

Dec 08
With EPS Growth And More, CSL (ASX:CSL) Is Interesting

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

CSLAU BiotechsAU Market
7D-4.2%-4.3%-2.8%
1Y-3.7%-3.1%5.8%

Return vs Industry: CSL matched the Australian Biotechs industry which returned -3.1% over the past year.

Return vs Market: CSL underperformed the Australian Market which returned 5.8% over the past year.

Price Volatility

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement3.9%
Biotechs Industry Average Movement9.1%
Market Average Movement8.6%
10% most volatile stocks in AU Market15.4%
10% least volatile stocks in AU Market3.7%

Stable Share Price: CSL is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CSL's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
191625,000Paul Perreaulthttps://www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.

CSL Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSL fundamental statistics
Market CapUS$91.24b
Earnings (TTM)US$2.38b
Revenue (TTM)US$10.31b

38.4x

P/E Ratio

8.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CSL income statement (TTM)
RevenueUS$10.31b
Cost of RevenueUS$4.47b
Gross ProfitUS$5.84b
ExpensesUS$3.47b
EarningsUS$2.38b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Feb 16, 2022

Earnings per share (EPS)4.96
Gross Margin56.68%
Net Profit Margin23.04%
Debt/Equity Ratio55.0%

How did CSL perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

43%

Payout Ratio

Valuation

Is CSL undervalued compared to its fair value and its price relative to the market?

38.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CSL (A$264.52) is trading above our estimate of fair value (A$238.38)

Significantly Below Fair Value: CSL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CSL is poor value based on its PE Ratio (38.4x) compared to the Global Biotechs industry average (32.8x).

PE vs Market: CSL is poor value based on its PE Ratio (38.4x) compared to the Australian market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: CSL is poor value based on its PEG Ratio (4.5x)


Price to Book Ratio

PB vs Industry: CSL is overvalued based on its PB Ratio (10.9x) compared to the AU Biotechs industry average (4.2x).


Future Growth

How is CSL forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSL's forecast earnings growth (8.5% per year) is above the savings rate (1.9%).

Earnings vs Market: CSL's earnings (8.5% per year) are forecast to grow slower than the Australian market (11.1% per year).

High Growth Earnings: CSL's earnings are forecast to grow, but not significantly.

Revenue vs Market: CSL's revenue (6.5% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: CSL's revenue (6.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CSL's Return on Equity is forecast to be high in 3 years time (26.1%)


Past Performance

How has CSL performed over the past 5 years?

14.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSL has high quality earnings.

Growing Profit Margin: CSL's current net profit margins (23%) are higher than last year (23%).


Past Earnings Growth Analysis

Earnings Trend: CSL's earnings have grown by 14.4% per year over the past 5 years.

Accelerating Growth: CSL's earnings growth over the past year (13%) is below its 5-year average (14.4% per year).

Earnings vs Industry: CSL earnings growth over the past year (13%) underperformed the Biotechs industry 48.2%.


Return on Equity

High ROE: CSL's Return on Equity (28.3%) is considered high.


Financial Health

How is CSL's financial position?


Financial Position Analysis

Short Term Liabilities: CSL's short term assets ($7.4B) exceed its short term liabilities ($3.1B).

Long Term Liabilities: CSL's short term assets ($7.4B) exceed its long term liabilities ($6.7B).


Debt to Equity History and Analysis

Debt Level: CSL's net debt to equity ratio (33.4%) is considered satisfactory.

Reducing Debt: CSL's debt to equity ratio has reduced from 121.5% to 55% over the past 5 years.

Debt Coverage: CSL's debt is well covered by operating cash flow (78.6%).

Interest Coverage: CSL's interest payments on its debt are well covered by EBIT (20.2x coverage).


Balance Sheet


Dividend

What is CSL current dividend yield, its reliability and sustainability?

1.08%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CSL's dividend (1.08%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.25%).

High Dividend: CSL's dividend (1.08%) is low compared to the top 25% of dividend payers in the Australian market (5.52%).


Stability and Growth of Payments

Stable Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CSL is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Paul Perreault (64 yo)

8.5yrs

Tenure

US$10,124,422

Compensation

Mr. Paul R. Perreault, B.A. (Psychology) has been the Chief Executive Officer and Managing Director of CSL Limited since July 1, 2013. Mr. Perreault serves as the Chief Executive Officer and Managing Direc...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD10.12M) is above average for companies of similar size in the Australian market ($USD3.78M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CSL's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: CSL's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CSL insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.


Top Shareholders

Company Information

CSL Limited's employee growth, exchange listings and data sources


Key Information

  • Name: CSL Limited
  • Ticker: CSL
  • Exchange: ASX
  • Founded: 1916
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$126.639b
  • Shares outstanding: 478.75m
  • Website: https://www.csl.com.au

Number of Employees


Location

  • CSL Limited
  • 45 Poplar Road
  • Parkville
  • Victoria
  • 3052
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/22 07:02
End of Day Share Price2022/01/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.